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A B S T R A C T   
Introduction: There is an ongoing digital revolution in the field of Parkinson’s disease (PD) for the objective 
measurement of motor aspects, to be used in clinical trials and possibly support therapeutic choices. The focus of 
remote technologies is now also slowly shifting towards the broad but more “hidden” spectrum of non-motor 
symptoms (NMS). 
Methods: A narrative review of digital health technologies for measuring NMS in people with PD was conducted. 
These digital technologies were defined as assessment tools for NMS offered remotely in the form of a wearable, 
downloadable as a mobile app, or any other objective measurement of NMS in PD that did not require a hospital 
visit and could be performed remotely. Searches were performed using peer-reviewed literature indexed data-
bases (MEDLINE, Embase, PsycINFO, Cochrane Database of Systematic Reviews, Cochrane CENTRAL Register of 
Controlled Trials), as well as Google and Google Scholar. 
Results: Eighteen studies deploying digital health technology in PD were identified, for example for the mea-
surement of sleep disorders, cognitive dysfunction and orthostatic hypotension. In addition, we describe 
promising developments in other conditions that could be translated for use in PD. 
Conclusion: Unlike motor symptoms, non-motor features of PD are difficult to measure directly using remote 
digital technologies. Nonetheless, it is currently possible to reliably measure several NMS and further digital 
technology developments are underway to offer further capture of often under-reported and under-recognised 
NMS.   
1. Introduction 
The use of digital health technology, some in combination with 
connected devices (e.g. smartphones), is on the rise to improve the 
management of medical conditions, including Parkinson’s disease (PD). 
Digital health technology covers a broad area of technical applications 
and includes devices worn on the body (in the form of watches, bracelets 
or devices embedded in clothing), smartphones, sensors embedded into 
a patient’s home (for example in smart beds) or analysis of regularly 
used appliances, such as computer keyboards. Ideally, such remote 
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measurement techniques should be non-disruptive to the person’s 
normal lifestyle. Specifically, the technology should allow for use any-
where without barriers, and should be feasible for use both at home and 
within the community. Digital technologies theoretically provide an 
opportunity to monitor people for extended periods of time, provided 
that participants comply with extended use, which has been a vexing 
issue in most studies thus far. Additionally, digital technologies poten-
tially allow for care to be delivered at home and in the community, 
thereby limiting the need for hospital visits [1]. Importantly, these 
technologies enable us to passively collect data in the background, and 
these data are therefore not influenced by rater or patient bias, which is 
often the case with subjective patient diaries [2]. Another concern with 
existing approaches is the attentional compensation which is typically 
associated with in-clinic sessions while patients know they are being 
observed [3]. In fact, these benefits have already led to the invention 
and testing for usefulness and reliability for many devices in PD and 
neurocognitive disorders [4], some of which have already made their 
way into clinical practice [5]. However, in the case of PD, the focus of 
digital technology has been almost exclusively on the motor symptoms 
associated with this disease, with devices measuring tremor, bradyki-
nesia, wearing-off, dyskinesia, gait patterns and falls [6,7]. Attempts 
have even been made to measure rigidity objectively [8]. Non-motor 
symptoms (NMS), which are pivotal to the natural history of PD and 
which are a crucial determinant of the patient’s and caregiver’s quality 
of life, have thus far received little attention as a target for objective 
measurements through digital technology, although the introduction of 
commercial systems to record heart rate, ECG and blood oxygen satu-
ration has raised the interest from both patients and healthy subjects. 
Monitoring and measurement of NMS in PD is complicated by the 
physiology of certain NMS which makes it difficult to objectively mea-
sure them, not only from a digital health perspective. Similarly, dedi-
cated non-motor scales are not always able to detect and correctly 
identify NMS [9], also bearing in mind these scales measure patient or 
clinician reported outcomes and not physiological processes. To date, 
the only relatively well-explored NMS aspect of PD in which wearable 
technology has been deployed, is the use of actigraphy for circadian and 
sleep disorders [10]. However, in recent years attempts have been made 
to address the objective assessment of some other NMS in PD. In addition 
to the dual challenge posed by first objectively measuring NMS and then 
transforming this into digital health outcomes, there is the lack of clear 
guidelines and criteria for the selection, technical validation, and clin-
ical validation of novel digital endpoints [11]. The use of 
technology-based digital devices should aim to supplement objective 
measures as well as the more commonly used subjective measures, 
including scales and questionnaires, in determining presence and 
severity of symptoms in the clinical management of PD beyond research 
projects [12,13]. In this narrative review we aim to describe the state of 
the art of digital health technology for objective assessment of NMS in 
PD. 
2. Methods 
We performed a review of digital health technology relating to NMS 
occurring in PD. The objectives of this review were to summarise the 
different types of digital technology currently in use to measure NMS in 
PD, as well as those technologies that hold promise for future use in PD, 
and to inform future non-motor research and health policies. The aim of 
this review was to provide a narrative overview and viewpoint of digital 
health technologies for NMS in PD, rather than a systematic review. 
The search strategy included the terms ‘Parkinson’ or ‘Parkinson’s’ 
combined with ‘gyroscope’, ‘accelerometer’, ‘technology’, ‘app’ or 
‘wearable’. The search was not limited by date, language, or study 
design. The searches were performed using peer-reviewed literature 
indexed databases (MEDLINE, Embase, PsycINFO, Cochrane Database of 
Systematic Reviews, Cochrane CENTRAL Register of Controlled Trials), 
as well as Google and Google Scholar by the first and second authors and 
conflicts were resolved with the senior authors of the manuscript. 
Reference lists of identified manuscripts were used to identify any other 
relevant studies. The final search was performed in December 2020. For 
the purpose of this review, digital technology was defined as digital 
assessment tools for NMS offered remotely in the form of a wearable, 
downloadable as a mobile app, or any objective digital measurement of 
NMS in PD that did not require a hospital visit and could be performed at 
home. Inclusion criteria were: 1) studies addressing digital health 
technology in people with Parkinson’s disease, and 2) measurement 
and/or monitoring of non-motor symptoms. Exclusion criteria were: 1) 
digital technologies in populations other than people with Parkinson’s 
disease, and 2) measurement and/or monitoring of motor symptoms. 
3. Results 
An overview of the 18 studies with identified technologies measuring 
NMS and wearable outcomes associated with NMS is provided in Table 1 
and examples are given in Fig. 1. 
3.1. Overall non-motor symptoms 
Currently, no objective measurements of general non-motor burden 
is available. Even though certain apps have used the availability of pa-
tients scoring self-reported outcome measures [14], these are still sub-
jective and come with the limitations of patient completed diaries. 
3.2. Orthostatic hypotension 
Among Parkinson’s-related cardiovascular abnormalities, ortho-
static hypotension (OH) is the most common and one of the better 
described conditions with an overall prevalence ranging from 10% to 
70%. OH is multifactorial in origin, as it can be iatrogenic, but also an 
intrinsic feature of PD occurring early in the course of the disease [15], 
as well as in the prodromal phase [16], with neuropathological studies 
confirming the presence of pathological alpha-synuclein deposits in 
central and peripheral regulatory nuclei [17]. In addition to OH, supine 
hypertension and nocturnal hypertension are other common problems 
in PD and detection is required as OH is associated e.g. with white 
matter laesions [18]. 
The gold standard for OH diagnosis is a standard blood pressure 
measurement in the supine and upright position or a head-up-tilt test in 
hospital settings, and for detection of supine or nocturnal hypertension 
the use of 24-h home monitoring [19]. Scaling down the standard de-
vices used for this, would enable blood pressure measurement in a home 
environment. For example, Hellman et al. reported continuous 
non-invasive arterial pressure monitoring in PD in patients who had 
documented OH compared to those without OH [20]. They showed that 
the wearable device was capable of reproducing findings made in a 
hospital setting, which was considered the ‘gold standard’ in this study. 
Vallelonga et al. compared ambulatory blood pressure monitoring 
(ABPM) for OH with office blood pressure measurement [21] to test the 
diagnostic accuracy of ABPM-based hypotensive episodes (Hypo-ep) and 
hypotension during periods of wakefulness (Hypo-aw). They showed a 
diagnostic accuracy of 87.6% to detect OH, suggesting that remote 
monitoring of blood pressure is feasible although the large device and 
monitor size are limitations. 
Further developments are likely to be expected to take on the form of 
smart watches. Several of such watches are in existence and are capable 
of measuring heart rate, blood pressure, and oxygen saturation. 
Currently, however, it would seem that only heart rate meets accuracy 
guidelines, but not the other vital sign measurements [22,23]. 
3.3. Sleep dysfunction 
Sleep dysfunction, such as onset and maintenance insomnia, are a 
common feature occurring in PD although with wide range estimate 
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Table 1 
Remote monitoring devices for non-motor symptoms in Parkinson’s disease. Abbreviations: OH: orthostatic hypotension; PD: Parkinson’s disease; RBD: Rapid 
Eye Movement Sleep Behavioural Disorder; PDSS: Parkinson’s disease sleep scale; PSG: polysomnography; NMSQ: Non Motor Symptoms Questionnaire; MMSE: Mini 
Mental State Examination.  
















(31 with OH and 21 
without) 
In clinic blood pressure 
measurements 
Continuous non-invasive arterial blood pressure. 
Similar proportion of participants with OH for 
both devices 
•One-off session of 
3 min 





•113 participants In clinic blood pressure 
measurements 
Continuous non-invasive arterial blood pressure. 
Two or more episodes with ≤15 mmHg systolic 
drop 75% diagnostic accuracy for OH. One or 
more episodes 93% specificity for OH 
•24 h blood 
pressure 
monitoring 







None Activity measure between participants with PD 
and controls differ significantly, particularly at 
nighttime •69 healthy 
controls 
•3 days and nights 
Perez-Lloret 






PDSS Significant moderate correlations between 
actigraphy and PDSS domains 
•21 healthy 
controls 
•7 days and nights 







Sleep diary Scores on subjective sleep correlated moderately 
with actigraphy-derived estimates, but only in 
participants with PD •14 healthy 
controls 
PDSS 
•7 days and nights Epworth Sleepiness Scale 







REM Sleep Behaviour 
Questionnaire 
Participants with RBD had higher number of 
activity bouts than those without RBD 
•2 weeks Scales for Outcomes in Parkinson’s 
disease (SCOPA) Sleep 







PSG Significant moderate correlations between 
actigraphy and polysomnography measures for 
sleep time and wake after sleep onset •1 night 







PSG For predicting RBD 95 wake bouts per night on 
actigraphy had 95.5% specificity, 20.1% 
sensitivity 85.7% positive predictive value 
compared to PSG 
•1 night 







Digit Span Backwards subtest (raw 
score) of the Wechsler Adult 
Intelligence Scale-III (WAIS-III) 
Working memory and verbal memory 
consolidation significantly associated with sleep 









Parkinson’s Disease Sleep Scale Percentage of time spent immobile correlated 
moderately with sleep/fatigue questions of the 
NMSQ and with PDSS •6 days and nights 
Excessive daytime 
sleepiness 






Epworth Sleepiness Scale Percentage of time spent immobile was 
significantly higher in those with ESS score ≥10 
•6 days and nights 











•6 days and nights 








Test Automated Battery 
Mini Mental State Examination 
Participants with excessive sleepiness had a trend 
towards poorer working memory 
•21 healthy 
controls 
•6 days and nights 







MDS-UPDRS part I Not available 
Montreal Cognitive Assessment 
Phonemic and semantic Fluency 
Brixton Spatial 
15 Words Test 
Benton Judgment of Line 
Orientation 
Letter Number Sequencing 
Symbol Digit Modalities 
Weiss et al., 2019 
[45] 
Body fixed sensor •96 participants 
with PD 
MMSE 
Montreal Cognitive Assessment 




(continued on next page) 
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regarding prevalence (20% up to 80%) reported in PD cross-sectional 
subjective assessments [24]. The data related to its progression during 
the course of the disease are heterogeneous, but nonetheless sleep 
problems have a high impact on quality of life in PD and are often missed 
in outpatient settings [25–27]. 
Polysomnography (PSG) remains the gold standard for monitoring or 
diagnosing sleep dysfunction in PD, but is expensive, not widely avail-
able and requires patients to stay in bespoke facilities overnight. 
Wearable sensors would offer an alternative as a simpler, cheaper, and 
probably effective strategy. Nocturnal accelerometers are already in 
relatively wide-spread use for sleep monitoring and are used as an 
outcome measure in research settings. These do not include EEG re-
cordings, which are required for direct assessment of sleep function, but 
only indirectly measure sleep-associated movements. Wrist worn 
actigraphy, containing tri-axial accelerometers, quantifies the amount of 
motor activity during daytime and night-time, as a measure of sleep and 
physiological diurnal patterns, and was approved by FDA to measure 
limb activity associated with movement during sleep for physiologic 
applications [10]. Several studies have shown the usefulness of actig-
raphy in PD and this has been recently reviewed by Zampogna et al. 
[28]. Examples of the use of actigraphy include the findings by e.g. 
Perez-Lloret et al. reported that actigraphy data in PD significantly 
correlated with PD Sleep Scale (PDSS) and patient-completed diary data 
related to sleep quality and daytime somnolence [29]. Maglione and 
colleagues [10] reported a positive correlation of night-time actigraphy 
for the assessment of sleep quality and quantity in PD with PSG showing 
that actigraphy may be useful as a measurement for total sleep time, 
sleep efficiency, and wake time after sleep onset although with some 
Table 1 (continued ) 






Validation against Measure used and findings 







Significant associations between % sedentary and 
active episodes and MMSE, also with number of 
sedentary bouts 







MMSE Less stable day-to-day rest-activity rhythm was 
associated with poorer executive, visuospatial, 
and psychomotor functioning, but not memory •7–10 days Neuropsychiatric testing 
Impulse control 
disorder 






Questionnaire for Impulsive- 
Compulsive disorder (QUIP) 
Number of medication acknowledgements 
correlated significantly with QUIP scores 
•6 days and nights 





with PD (and their 
partners) 
Amount of times getting up at 
night for toilet visits 
Sensor measured the amount of times that 
participants got out of bed; significant discrepancy 
between partner reported and objective measure 
•1 night 






Time to move food from plate to 
mouth 
Objective measure for time taken 
•7 healthy controls  
Figure 1. Examples of non-motor areas in Parkinson’s disease where wearable and remote technologies have been investigated and non-motor areas 
where further developments are expected based on technologies available in other conditions. Abbreviations: GI: gastrointestinal; GPS: global positioning 
system; ADL: activities of daily living. 
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variability. However, as actigraphy records bouts of activity, there are 
difficulties in distinguishing Rapid Eye Movement Behaviour Disorder 
(RBD) from awake time using actigraphy. Several studies have reported 
the use of actigraphy to detect RBD [30,31], in which PD patients with 
RBD had significantly higher numbers of bouts of activity, scored as 
“awake”, on actigraphy. When compared to an RBD questionnaire, the 
actigraphy outcomes had low sensitivity for detecting RBD. 
Tri-axial accelerometers are similar to actigraphy but are able to 
better quantify the amount of motor activity. Using such a device, 
Klingelhoefer et al. reported that periods of immobility (periods during 
which no significant motor activity was detected) correlated well with 
PD Sleep Scale (PDSS) [32] although the association between wearables 
sensor output and motor activity captured by Hauser diary data was 
poor, perhaps supporting the benefits of objective rather than subjective 
(diary-based) outcomes. For daytime sleepiness, Kotschet et al. showed 
that the immobility measure of a tri-axial accelerometer was correlated 
with high Epworth Sleepiness Scores (ESS) [33]. 
Future developments in this field will be likely to draw from the 
experience gained in other fields of neurology, including Alzheimer 
disease. Examples of remote sleep measurement that are likely to make 
their way into PD are mobile phone sleep trackers, bed- or under- 
mattress fitted sensors (‘smart beds’), and wearable electroencephalo-
gram headbands [34], but these have yet to be validated for use in PD. 
Especially ‘smart beds’ could prove useful and some evidence has 
already been presented that they are able to quantify nocturnal move-
ments, including turning, being in upright position and walking during 
nocturnal period, in PD [35]. The usefulness of such sleep measurements 
is contained in its objectiveness, instead of patient and carer (sleep) 
diaries, which come with inherent inaccuracies and can be discrepant 
between patients and carer [36]. 
3.4. Impulse control disorder 
Impulse control disorders (ICD) are characterised by the inability to 
assert self-control in emotions and behaviours, leading to compulsive 
and/or impulsive actions that harm oneself or others. The pathways 
involved in ICD have been implicated in rapid eye movement sleep 
behaviour disorder, constipation, and cognitive impairment [37]. 
Despite it being an important problem in PD [38], only one study has 
examined the role of wearables in ICD. Using a 3-axial accelerometer 
device, Evans and colleagues showed that ratings of ICD, in the form of 
Questionnaire for Impulsive-Compulsive Disorder in Parkinson’s 
Disease-Rating Scale (QUIP-RS) scores, was strongly positively associ-
ated with the number of acknowledgements per intake of oral medica-
tion in a small cohort of 25 PD patients. The intake was recorded by 
having the patient record the intake of medication by pressing a button 
on the watch; for this simple procedure it would not be necessary to have 
a tri-axial accelerometer or similar device but given the ease with which 
this can be recorded it would be easy to add it as a feature to any 
wearable device. This is also one of the few studies looking at wearable 
outcome measures that do not rely on motor markers to serve as a sur-
rogate, but instead relied on assessing ICD severity by the amount of 
times a patient acknowledged the intake of medication using a paradigm 
embedded in the wearable device use [39]. 
Further developments in the objective capture of ICD could involve 
the analysis and quantification of internet use as it has been suggested 
these are linked in PD patients. More specifically, Wu et al. showed that 
PD patients with ICDs had a relative increased tendency towards 
excessive use of the Internet compared to those without ICDs as well as 
healthy controls [40]. However, in this study the information on internet 
use was gathered through means of a face-to-face structured interview 
and all participants had specifically consented to this, in addition to the 
self-reported documentation of type of websites they spend most time on 
whilst online. This is likely to be a limiting factor in the further devel-
opment of objective measures for ICD based on Internet usage, as well as 
the clear privacy-related aspects. 
3.5. Cognition 
In recent years many forms of digital technology have been devel-
oped to measure cognitive performance. Although many of these tech-
nologies have not been tested in people with PD, there are a number of 
studies in Alzheimer’s disease. Due to its nature, digital health tech-
nologies assessing cognition range from wearable sensors to phone apps 
covering various aspects of cognitive function, such as the “Remote 
Assessment of Disease and Relapse – Alzheimer’s Disease” (RADAR-AD), 
using remote monitoring to actively and passively measure cognitive 
and affective biomarkers [34]. Examples of how cognitive performance 
can be measured include the passive use of Global Positioning System 
(GPS) movement trajectories or deviation from navigation tools for 
spatial navigationa and memory, or the more active use of phone apps to 
measure performance on gamified/virtual reality tests as a measure for 
planning skills and task completion [34]. Other examples include, but 
are not limited to, app based technologies to assess spatial navigation, 
memory and other cognitive functions, phone app measurements using 
the performance on gamified/virtual reality tests for planning skills, 
smart home sensors for opening/closing of doors and window as a 
measure for daily activities, and speech analysis for dysnomia (https:// 
mezur.iohttps://altoida.com) [34]. 
In PD, several studies have shown that gait parameters measured by 
conventional wearable triaxial sensors could be useful as an indirect 
indicator of cognitive decline, although further studies are required to 
assess confounders for the observed associations, and ideally such 
monitoring should move away from indirect markers of cognitive per-
formance. A UK based study measured gait parameters using a single 
axis sensor and reported specific patterns for dementia typical for PD, 
dementia with Lewy bodies, and Alzheimer’s disease [41]. Terashi and 
colleagues have recently shown that in a cohort of 106 Japanese non 
fluctuating PD patients the gait acceleration amplitude showed a mod-
erate positive association with Mini Mental State Examination (MMSE) 
scores [42]. This latter relation remained significant after the correction 
for UPDRS postural instability and gait disorder scores. The same group 
of researchers reported similar findings in drug-naïve PD patients, where 
daily physical activity was moderately positively associated with Frontal 
Assessment Battery and Behavioural Assessment of Dysexecutive Func-
tion scores. Significant associations were not present for other cognitive 
assessments, including MMSE, Beck Depression Inventory and Stark-
stein’s apathy scores [43]. In another study, in a cohort of 47 German PD 
patients, higher levels of daily activity measured with a back worn 3D 
accelerometer were associated with better cognitive scores [44]. How-
ever, Weiss and colleagues were unable to demonstrate a relation be-
tween timed up-and-go assessment, as measured by a body-fixed sensor, 
in PD patients with cognitive outcome measures (MoCA and MMSE) 
[45]. 
Recently, Mirelman and colleagues showed that nocturnal move-
ments, including turning and being in upright position and walking 
during nocturnal period, were correlated to dysexecutive patterns using 
Trail Making Test scores which were inversely correlated to the number 
of rotations during the night. In addition, it was shown that Non-Motor 
Symptoms Scale scores were also inversely associated with turning in 
bed at night and nocturia [35]. In addition, circadian disruption, inde-
pendent of sleep, has been investigated as a marker for cognition, and a 
decreased day-to-day rest-activity rhythm, as measured by actigraphy, 
was associated with poorer executive, visuospatial, and psychomotor 
functioning. Interdaily stability of circadian patterns predicted 14% of 
the variation occurring in executive function, psychomotor and visuo-
spatial performance in a cohort of 35 PD patients [46]. 
A prospective, longitudinal, single-centre cohort study known as the 
‘Personalized Parkinson Project’, is aiming to address the usefulness of a 
highly advanced smartwatch (including 3-axial accelerometers, a goni-
ometer, a barometer, and sensors for skin temperature, environmental 
light and sound) in a large cohort who will wear the watch for up to 3 
years. This study also includes a wide battery of neuro-psychological 
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assessments that will be measured annually as outcome in 650 partici-
pants. This study is currently underway, and the results are awaited 
[47]. 
3.6. Depressive symptoms 
Even though no studies appear to exist looking at any direct rela-
tionship between depressive symptoms and measurable wearable sensor 
outcomes in PD, two studies have shown some evidence for associated 
changes that might be indicative of depressive symptoms. One study 
reported that PD patients with depressive symptoms showed a more 
pronounced systolic blood pressure drop on head up tilting and a higher 
prevalence of orthostatic hypotension compared to non-depressed pa-
tients even though there were no 24 h BP recordings performed in either 
group [48]. Similarly, PD patients with a geriatric depression score of 
five or over had higher adjusted levels of systolic, diastolic, and mean 
blood pressure dipping in addition to nocturnal high systolic pressure, 
and the presence of moderate to severe depressive symptoms was 
inversely associated with systolic dipping in a regression model [49]. 
Even though such measurements could be arguably used to capture 
depressive symptoms, it may be better to rely on more direct measures 
rather than surrogate markers as these often rely on associations and 
could be confounded by many factors, such as disease duration and age. 
3.7. Gastrointestinal 
Gastrointestinal dysfunction in PD affects the whole gastrointestinal 
tract and can be observed in each stage of the disease, from the pro-
dromal to the advanced phases [50]. Especially constipation is a com-
mon feature with an overall prevalence ranging from 11 to 83%, and is 
considered as one of the earliest symptoms in PD and a risk factor for the 
development of this condition [51]. Also, other gastrointestinal prob-
lems, including dysphagia, are common in the later stages of PD with a 
major impact on quality of life and a pivotal role in prognosis (morbidity 
and mortality) in advanced PD [52,53]. 
There are no validated direct measures of function of gastrointestinal 
dysfunction in PD, although such efforts are underway to test digital 
health technology measuring these symptoms in PD. In fact, recently a 
smart belt for such symptoms has been developed and has received a CE 
mark, showing the device meets European standards on safety, health or 
environmental requirements (https://ec.europa.eu/research/participan 
ts/documents/downloadPublic?documentIds=080166e5b77ec 
f58&appId=PPGMS). The smart belt is composed of five sensors (four 
acoustic and one for electrogastrogram) and an elastic band. The device 
records bowel sounds (using the acoustic sensors) and the electrical 
activity generated by the muscles’ contractions triggered by stomach 
and intestines during digestion (electrogastrogram sensor). To date, no 
results have been published regarding the use of this belt and its out-
comes in PD. Currently also other efforts are being made to measure 
other gastrointestinal and associated symptoms in PD, including 
impulsive eating disorders, appetite-related NMS, such as weight 
change, as well as dysphagia. Here, “plate-to-mouth” time, measured 
through a tri-axial wrist-worn sensor, has already been validated as an 
objective measure for eating behaviour in PD [54]. 
3.8. Urinary 
Urinary symptoms are common in PD, as shown by studies where 
night-time urinary frequency (nycturia) was reported by 53% of female 
and 63% of male PwP, but also showing common urinary urgency and 
daytime frequency [55]. Interestingly, several groups have separately 
reported that the presence of urinary symptoms at diagnosis is a sig-
nificant biomarker for more rapid functional decline [56–60]. Capturing 
urinary symptoms in PD may, therefore, aid in other areas of PD in 
addition to their impact on quality of life. 
Only nocturia has been studied using multisite inertial sensors in the 
home setting, providing remote monitoring. In this study patients had an 
inert registration device mounted in their home which picked up data 
from a body-fixed sensor collecting quantitative nocturnal movements 
of PD patients and comparing these outcomes to patients and spouse 
reported outcomes. Here it was shown that nocturia, measured by the 
number of times a patient got out of bed during the night, could be 
effectively picked up by the sensors, supported by sleep diaries [36]. 
Future monitoring of urinary (and gastrointestinal) NMS in PD could 
be achieved by further developing and validating the use of ‘smart toi-
lets’. Such toilets are capable of calculating urine flow rate and volume, 
classifying stool according to the Bristol stool form scale, and able to 
identify individual users through their fingerprint and the distinctive 
anoderm features [61]. Such devices could hold great potential in 
measurement and classification of urinary NMS in PD. 
4. Discussion 
Currently very few objective measures for the multifaceted NMS of 
PD exist. As such, it is not surprising to find that studies have tried to 
objectify and quantify these symptoms in the form of wearable sensors 
(Table 1). Nonetheless, few studies have looked at deploying wearable 
and remote technology for the measurement and monitoring of NMS in 
PD, but some technologies used to measure NMS in other conditions 
hold promise for future use in PD (Fig. 1). 
As with any other symptom, the objective measurement and digital 
monitoring of NMS in PD requires a consensus to evaluate the quality 
and usefulness of digital devices, including but not limited to clinical 
utility, user experience, and governance for collection [62]. An addi-
tional difficulty, unlike the case with motor symptoms, is posed by the 
fact that NMS are often difficult to measure. Several suggestions have 
been made towards a standardised approach for digital healthcare 
technology and one of the most recent ones, by Goldsack and colleagues, 
includes a three-step approach: (1) verification (systematic evaluation 
by manufacturers), (2) analytical validation (valuation of processed data 
and testing on human subjects), and (3) clinical validation (evaluation of 
identification, measurement, and prediction of meaningful clinical, 
biological, physical, functional state, or experience in the specified 
context of use) [62]. From the available evidence on digital health 
technology for NMS, studies identified here would fall into category 3, 
but only with regards to the identification element of this category. In 
addition, it should be noted that some evidence presented here is based 
on indirect markers for specific NMS based on motor outcomes. None-
theless, such markers (mostly bradykinesia and dopaminergic by 
default) of NMS based on wearable and objective motor measures, might 
be a good starting point to improve at least some NMS in PD. As an 
example, the number of acknowledgements per intake of oral medica-
tion appears to be strongly correlated to repetitive behaviour which is 
typically seen with ICD [39]. In addition, arguments have been made to 
suggest that it is not necessary to have exact measurements of a NMS in 
question, as long as the symptom of interest can be related to an outcome 
and lead to a management pathway with therapeutic intervention after 
identification [63,64]. Focusing on what correlates best to subjective 
patient disability, rather than subjective assessments as many in-clinic 
assessments may be biased due to e.g. attentional bias [3]. 
Once devices and digital technology have been developed and vali-
dated for NMS in PD, a further distinction needs to be made to define 
how this technology is to be used in clinical practice. Here, the example 
set by the National Institute for Health and Care Excellence (NICE) in the 
United Kingdom can serve as a guide towards classification of this kind 
of technology for the use in PD. The NICE guidelines propose a three- 
tiered system to classify digital health technologies, where evidence 
tiers are cumulative which means that a technology must meet all 
standards in both previous tier(s) and its own tier. In tier 1 the digital 
technology has no measurable patient outcomes but provides services to 
the health and social care system; in tier 2 the technology informs about 
a condition, provides simple monitoring, or allows two-communication 
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between patient and health care professional; and in tier 3 the tech-
nology additionally allows for preventative changes, self-management, 
treatment, active monitoring, impact calculator, or diagnosis of a con-
dition [65]. The majority of the current studies that have looked at 
remote monitoring for NMS in PD would classify as tier 2 and further 
efforts are needed to move to tier 3 where NMS outcomes can be 
measured directly and trigger an intervention. At this stage, current 
limitations to the objective measurement of NMS, including recall bias 
affecting outcomes depending on the clinical scales or diaries used for 
addressing the NMS [2,66,67], will have been overcome. 
Other factors that need to be overcome when it comes to objective 
digital monitoring of NMS is compliance, especially given the fact that 
PD results in motor and cognitive impairment which may be relevant for 
at least some remote and wearable technologies. So far, limited evidence 
has shown that compliance levels with wearable technology is relatively 
high for PD patients. Cohen et al. showed that compliance rates were 
reduced by 30% over a 6-month period [68], confirmed by another 
study where the 6-month compliance rate was 62–68% in two cohorts of 
953 participants in total [69]. The main predictors for adherence appear 
to be caregivers’ burden and patients’ self-rated health status [70]. The 
study by Cohen et al. also showed an interesting observation in that 
daily smartwatch data streaming patterns peaked around mid-day and 
dropped sharply in the evening hours [68], perhaps indicative of a 
physiological circadian pattern [71]. 
Examples on the use of wearable sensor outcomes to guide treatment 
decisions are already available, albeit mostly involving motor outcomes. 
One such study showed that the use of a tri-axial wrist worn device for 
monitoring motor outcomes had an additional benefit on the increase in 
On-time after pharmacist-led medication review in 27 patients with PD 
[72]. At the same time the use of the wearable sensor in this study did 
not improve non-motor outcomes, although it should be noted that only 
a dichotomous outcome measure, the Non-Motor Symptoms Question-
naire, was used and treatment decisions were based on motor outcomes 
only [72]. One could imagine, however, that if wearable sensor out-
comes, as outlined in this review, are used to identify NMS that would 
otherwise go unrecognised, this would have a great impact on treatment 
and quality of life. Examples include depressive symptoms and cognitive 
impairment, which are not only debilitating in themselves, but are 
moreover independent risk factors for non-adherence [73], and recog-
nition of these symptoms could additionally lead to motor outcome 
improvements. 
5. Conclusions 
Following the increased availability and use of wearable technology 
in PD, the focus of these technologies is now also slowly shifting towards 
the broad NMS spectrum in this disease. Here, we have aimed to provide 
an overview of the current knowledge on this topic and show that, 
although the nature of NMS makes them difficult to objectively measure, 
further development and building on experience gained in other con-
ditions may still lead to feasible capture of NMS. Although it is difficult, 
based on the currently available evidence, to make recommendations for 
the use of digital technology outcomes for NMS in clinical practice, 
evidence for these devices is clearly evolving and such advice may 
become available in the not too distant future. 
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